GleamWall
中文EN

PRAX Praxis Precision Medicines, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1689548 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY365.0%
TTM net income YoY-80.8%
TTM EPS YoY-41.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-3,927.5%
Net margin-3,658.5%
FCF margin-3,067.4%
EBITDA margin-3,925.4%

Returns

ROE-75.2%
ROA-67.2%
ROIC (approx.)-113.5%
Asset turnover0.02x

Leverage & solvency

Liabilities / assets13.3%
Debt / equity0.00x
Current ratio5.18x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-10.9%
Payout ratio—
Capex / revenue0.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———$0$0$0$0$7.46M
R&D expense$64.20M$69.42M$77.99M$77.51M$65.80M$63.01M$60.81M$56.29M
SG&A expense$42.71M$27.49M$27.87M$19.54M$12.56M$13.06M$13.92M$15.13M
Operating income-$106.91M-$96.90M-$105.86M-$97.04M-$78.36M-$76.07M-$74.73M-$63.96M
Net income-$94.23M-$83.72M-$92.56M-$88.91M-$73.93M-$71.13M-$69.30M-$58.68M
EBITDA-$106.88M-$96.87M-$105.82M-$97.02M-$78.34M-$76.02M-$74.68M-$63.91M
EPS (basic)-3.23-2.87-3.20—-3.36-3.31-3.29—
EPS (diluted)-3.23-2.87-3.20—-3.36-3.31-3.29—
Weighted avg. shares (diluted)29.18M29.13M28.88M—21.98M21.47M21.06M—
Balance sheet
Cash & equivalents$361.85M$474.76M$536.33M$357.33M$149.53M$157.41M$165.57M$215.79M
Short-term investments$383.47M$283.79M$250.53M$242.00M$117.63M$143.86M$162.42M$177.19M
Current assets$762.80M$771.90M$797.77M$610.91M$273.84M$306.58M$333.57M$404.37M
PP&E, net$1.90M$492,000$170,000$147,000$174,000$258,000$247,000$230,000
Intangibles—$773,000—$0————
Total assets$1.31B$1.39B$1.46B$937.91M$396.39M$452.83M$478.74M$483.11M
Current liabilities$52.50M$49.06M$50.24M$59.77M$52.88M$48.61M$39.52M$37.55M
Total liabilities$52.50M$49.06M$50.24M$59.77M$52.88M$48.61M$39.52M$37.66M
Shareholders' equity$1.26B$1.34B$1.41B$878.14M$343.50M$404.22M$439.21M$445.45M
Shares outstanding27.95M27.92M27.86M25.20M21.17M21.04M20.34M19.42M
Cash flow statement
Operating cash flow-$81.74M-$77.54M-$86.15M-$76.33M-$65.06M-$54.68M-$53.01M-$56.12M
Capital expenditure$1.55M$245,000$62,000$0$0$56,000$0$0
Free cash flow-$83.29M-$77.79M-$86.21M-$76.33M-$65.06M-$54.73M-$53.01M-$56.12M
Investing cash flow-$32.10M$10.98M-$344.27M-$328.39M$50.41M$17.89M-$51.06M-$10.92M
Financing cash flow$929,000$4.57M$609.43M$612.52M$6.76M$28.63M$54.27M$113.77M
Depreciation & amortization$33,000$33,000$39,000$28,000$19,000$46,000$47,000$47,000
Stock-based compensation$14.89M$11.31M$17.11M$9.94M$7.45M$7.77M$8.79M$8.57M

Free plan shows the latest 8 periods; Pro shows all 29 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.